Immune Tolerance Induction After Liver Transplantation
Recruiting now · Phase 1/Phase 2
Conditions studied: Liver Transplantation, Immune Tolerance, Immune Tolerance/Drug Effects, Graft Survival, Hematopoietic Stem Cell, Chimerism, Immunosuppression After Liver Transplantation, Immunosuppression Disorders, End Stage Liver Disease
In brief
This clinical trial is being conducted to help liver transplant recipients safely discontinue toxic immunosuppressive drugs years after surgery. Lifelong use of these drugs is the current standard, but they come with life-threatening side effects. UCLA has pioneered this "Delayed Tolerance" approach, achieving success in numerous kidney recipients now living drug-free. The process uses a conditioning regimen followed by donor stem cell infusion to retrain the immune system to accept the liver as "self."
Key facts
- Study ID
- NCT07269041
- Run by
- University of California, Los Angeles
- People needed
- 12
- Starts
- 2026-02-20
- Expected to finish
- 2033-01-01
- Last updated by the study team
- 2026-03-12
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- UCLA Health 200 Medical Plaza — Los Angeles, California, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.